The current average analyst rating on the shares is "buy", with 12 "strong buy" or "buy" recommendations, 1 "hold" and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for REGENXBIO Inc. is $22.50, about 114.3% above its August 5 closing price of $10.50.
Outlook and cash runway
The company said it expects its cash runway to fund operations into Q4 2027. Regenxbio said it is on track to initiate the RGX-202 BLA submission in Q3 2026, with potential approval in 2H 2027. Topline data from pivotal wet AMD studies are expected in Q4 2026.
Milestone payment — The $100 million AbbVie milestone payment for the first patient dosed in the NAAVIGATE study drove the revenue increase.
Royalty decline — A decrease in Zolgensma royalty revenue due to U.S. patent expiration partially offset revenue gains.
R&D expenses — Lower manufacturing and clinical trial costs for sura-vec and NAVSUNLI pivotal trials reduced research and development expenses.
Quarterly revenue and profit surge
Regenxbio's second-quarter revenue surged year over year, driven by a $100 million AbbVie milestone payment. The company also posted net income in the quarter after a prior-year loss.
RGNX•
